Special Issue

Current Challenges and Future Perspectives of Antimicrobial Therapy

Message from the Guest Editors

Current challenges in antimicrobial therapy focus on the urgent global crisis of antimicrobial resistance that manifests when microorganisms, such as bacteria, fungi, or viruses, through various mechanisms, undergo resistance against the current therapeutic arsenal. This Special Issue aims to provide valuable insights into the topic of antimicrobial therapy (antibiotics, antimycobacterials, antifungals, and antivirals) in the context of the emergence of antimicrobial resistance, through a diverse collection of articles and reviews. Ongoing research, public awareness and education, and international collaboration play an important role in combating AMR and preserving the efficacy of antimicrobials for future generations.

Guest Editors

Dr. Carmen Maximiliana Dobrea

Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 2A Lucian Blaga St., 550169 Sibiu, Romania

Dr. Anca-Maria Arseniu

Preclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania

Deadline for manuscript submissions

31 May 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/257931

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).